A multicenter randomized trial comparing rabeprazole and itopride with functional dyspepsia in Japan: the NAGOYA study

A multicenter randomized trial comparing rabeprazole and itopride with functional dyspepsia in Japan: the NAGOYA study - A multicenter randomized trial comparing rabeprazole and itopride with functional dyspepsia in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013961

Enrollment

130

Registered

2014-05-20

Start date

2006-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia

Interventions

rabeprazole group itopride group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Functional dyspepsia patients, in whom organic disease underwent upper endoscopy had been excluded, who met the Rome III criteria

Exclusion criteria

Exclusion criteria: 1) history of gastrectomy 2) organic brain disease or schizophrenia 3) alcoholism or other abuse disorder 4) serious hormonal imbalances 5) serious heart, liver, kidney or hematopoietic disease 6) history of hypersensitivity to either of the test agents 7) pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Change Rates in dyspepsia scores (FD scores) between pretreatment (100%) and each time-point	—

Secondary

Measure	Time frame
sub-analysis in FD scores of epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS) based on the Rome III criteria	—

Countries

Japan

Contacts

Public ContactTakeshi Kamiya

Nagoya City University Graduate School of Medical Sciences Gastroenterology and Metabolism

kamitake@med.nagoya-cu.ac.jp052-853-8211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026